| Prev Close | 44.23 |
| Open | 44.59 |
| Day Low/High | 43.68 / 44.69 |
| 52 Wk Low/High | 18.93 / 59.25 |
| Volume | 2.88M |
| Avg Volume | 9.25M |
Canopy Growth Corp. (CGC)
44.34
0.11
0.25
NYSE : Process Industries
| Exchange | NYSE |
| Shares Outstanding | 343.58M |
| Market Cap | 15.23B |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Canopy Growth
Yesterday I reestablished a long position in Canopy Growth - which has been on my Best Ideas List since early January, 2019. The shares are responding well to this news.
With Tilray, You Won't Win Any Valuation Arguments
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Further Bidding
Bidding further to the following longs (but slightly below the market): , and .
Tilray Is Not My Favorite Canadian Cannabis Stock
Apparently, this game is all about growth right now. It certainly is not about margins.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
New CGC Move
I am back long Canopy Growth (very) small (I bought the opening). Moved up my buy entry price in light of a market that seems to be more accepting of speculative stocks.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Chart of the Day: Vetting the Value of Cannabis Companies
Assessing Aurora and its peers, strictly on the numbers.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz Is the Perfect Problem Solver for Aurora Cannabis
Peltz's addition should pacify a persistent critique of the company.
Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
Buy Levels
Here are some of my individual buy levels of stocks that I want to add to or reestablish on weakness: * $157.50 * $1625 * $1150 * $42 * $55 * $46 * $46.50 * $182.50 * $31 * $40 * $23 * $65 * $16.75 * $35 * $27.75 * $60 * $95 * $48 * $87.50 Note: Lon...
Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Nelson Peltz Could Be Key to Cannabis in Consumer Packaged Goods
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
Aurora Cannabis Builds Momentum, Enter Nelson Peltz
The plan is for Peltz to help the firm in maximizing potential markets to target.
Melius Research Launches Cannabis Industry Coverage
In its first report on cannabis companies, Melius says prices are high.
Jim Cramer: My Best Stock Picks for Cannabis and China
And why I won't recommend any other stocks in these markets, right now.
Revisiting Pot Stocks
A week ago, in 'Up In Smoke' on Feb. 19th, I soured on the short term price outlook for the pot stocks: Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is...
A Creative Way to Play Cannabis Stock Canopy Growth
If you are looking to invest in the fast-growing pot sector, this Canadian cannabis startup has been in early on the action.
Up In Smoke?
Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is extended and looks like it might be "rolling over" (awful pun!) technically. Canopy Growth is on my Best...
Now Isn't the Time to Gauge Marijuana Stocks
Right now they are speculative growth stocks through and through.
In Simpatico With the Very Reverend James
Rev Shark and I are in simpatico on: * The Bull Market In Complacency (which I discuss in my opener today) * A Possible Change in Market Complexion The former I am relatively certain of. The later will be contingent on a turn down in the absolute pe...
Cannabis Stocks Are Getting Their Second Wind
Let's check out the charts of four big names in the space.
SLANG Is the Cannabis IPO to Watch This Week
While consolidation may be key to the cannabis market in 2019, this IPO is worthy of a deeper dive.
Excuse Me, Would You Like Some Cannabis With Your Coffee?
CBD could make coffee an around the clock craze.
